RecruitingPhase 3

A Long-term Follow-up Trial of Patients Previously Treated With Imlifidase Prior to Kidney Transplantation and a Non-comparative Transplanted Patient Group

Austria, Czechia, France150 participantsStarted 2023-07-03

Plain-language summary

A prospective, post-authorisation long-term follow-up trial of patients previously treated with imlifidase prior to kidney transplantation, including a non-comparative concurrent reference cohort.

Who can participate

Age range19 Years – 76 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Signed Informed Consent obtained before any trial-related procedures * Willingness and ability to comply with the protocol * Previously transplanted in the clinical trial 20-HmedIdeS-19 (PAES) Exclusion Criteria: * Inability by the judgment of the investigator to participate in the trial for other reasons

What they're measuring

Graft failure-free survival (%) up to 5 years after imlifidase enabled transplantation (imlifidase cohort only)

Timeframe: 5-years after transplantation

Trial details

NCT IDNCT05937750

SponsorHansa Biopharma AB

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2030-04-30

Contact for this trial

Central Contact

+46 46 16 56 70 clinicalstudyinfo@hansabiopharma.com

View on ClinicalTrials.gov More Long Term Efficacy and Safety trials